Immunovia AB【0G8X】銘柄情報

Immunovia AB (0G8X) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

191.40

( - )

買値

191.40

売値

191.40

出来高

0.00 日の範囲 0.00

191.40 52 週間の範囲 191.40

時価総額

128.748B

前日終値

191.40

始値

時刻

0.1922

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

SEK 5,936,873

発行済株式数

672,666,892

配当利回り

PER

-0.82

1 株当たり利益 (EPS)

-0.24

歳入

920k

純利益

-106.56M

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (pu... Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden. 詳細を表示

セクター

業界

ウェブサイト

www.immunovia.com

本社

Lund, Sweden

設立

2026

Immunovia AB is listed in the sector of the ロンドン証券取引所 with ticker 0G8X. The last closing price for Immunovia AB was SEK191.40. Over the last year, Immunovia AB shares have traded in a share price range of SEK 191.40 to SEK 191.40.

Immunovia AB currently has 672,666,892 shares in issue. The market capitalisation of Immunovia AB is SEK128.75 billion. Immunovia AB has a price to earnings ratio (PE ratio) of -0.82.

Immunovia announces determined exercise price for warrants series TO 3

Immunovia announces determined exercise price for warrants series TO 3 PR Newswire LUND, Sweden, March 27, 2025 LUND, Sweden, March 27, 2025...

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, March 24...

Immunovia initiates search for a new CFO to support commercialization in the USA

Immunovia initiates search for a new CFO to support commercialization in the USA PR Newswire LUND, Sweden, Feb. 21, 2025 LUND, Sweden, Feb. 21...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND...

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	191.4	191.4	191.4	22037	191.4	DE
52	191.4	191.4	191.4	37547	191.4	DE
156	191.4	191.4	191.4	13959	191.4	DE
260	191.4	191.4	191.4	8325	191.4	DE

0G8X - Frequently Asked Questions (FAQ)

What is the current Immunovia AB share price?

The current share price of Immunovia AB is SEK 191.40

How many Immunovia AB shares are in issue?

Immunovia AB has 672,666,892 shares in issue

What is the market cap of Immunovia AB?

The market capitalisation of Immunovia AB is SEK 128.75B

What is the 1 year trading range for Immunovia AB share price?

Immunovia AB has traded in the range of SEK 191.40 to SEK 191.40 during the past year

What is the PE ratio of Immunovia AB?

The price to earnings ratio of Immunovia AB is -0.82

What is the cash to sales ratio of Immunovia AB?

The cash to sales ratio of Immunovia AB is 140.97

What is the registered address of Immunovia AB?

The registered address for Immunovia AB is Medicon Village, Lund, Skåne County, 223 63

What is the Immunovia AB website address?

The website address for Immunovia AB is www.immunovia.com

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Immunovia AB (0G8X)